Evidence map›Paper›PMID 37642487›Full record

ArticleMicrobiologyOpen2023

Isolation and functional analysis of phage-displayed antibody fragments targeting the staphylococcal superantigen-like proteins.

Ida Alanko, Rebecca Sandberg, Eeva-Christine Brockmann, Carla J C de Haas, Jos A G van Strijp, Urpo Lamminmäki, Outi M H Salo-Ahen

Open access · goldAbstract read
In one paragraph

Article in MicrobiologyOpen, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ida AlankoFaculty of Sciences and Engineering, Pharmaceutical Sciences Laboratory (Pharmacy) & Structural Bioinformatics Laboratory (Biochemistry) Turku, Åbo Akademi University, Turku, Finland.ORCID 0000-0003-0188-6467
Rebecca SandbergFaculty of Sciences and Engineering, Pharmaceutical Sciences Laboratory (Pharmacy) & Structural Bioinformatics Laboratory (Biochemistry) Turku, Åbo Akademi University, Turku, Finland.
Eeva-Christine BrockmannDepartment of Life Technologies, University of Turku, Turku, Finland.
Carla J C de HaasDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Jos A G van StrijpDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Urpo LamminmäkiDepartment of Life Technologies, University of Turku, Turku, Finland.
Outi M H Salo-AhenFaculty of Sciences and Engineering, Pharmaceutical Sciences Laboratory (Pharmacy) & Structural Bioinformatics Laboratory (Biochemistry) Turku, Åbo Akademi University, Turku, Finland.
Åbo Akademi University · FIUniversity of Turku · FIUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus produces numerous virulence factors that manipulate the immune system, helping the bacteria avoid phagocytosis. In this study, we are investigating three immune evasion molecules called the staphylococcal superantigen-like proteins 1, 5, and 10 (SSL1, SSL5, and SSL10). All three SSLs inhibit vital host immune processes and contribute to S. aureus immune evasion. This study aimed to identify single-chain variable fragment (scFvs) antibodies from synthetic antibody phage libraries, which can recognize either of the three SSLs and could block the interaction between the SSLs and their respective human targets. The antibodies were isolated after three rounds of panning against SSL1, SSL5, and SSL10, and their ability to bind to the SSLs was studied using a time-resolved fluorescence-based immunoassay. We successfully obtained altogether 44 unique clones displaying binding activity to either SSL1, SSL5, or SSL10. The capability of the SSL-recognizing scFvs to inhibit the SSLs' function was tested in an MMP9 enzymatic activity assay, a P-selectin glycoprotein ligand 1 competitive binding assay, and an IgG1-mediated phagocytosis assay. We could show that one scFv was able to inhibit SSL1 and maintain MMP9 activity in a concentration-dependent manner. Finally, the structure of this inhibiting scFv was modeled and used to create putative scFv-SSL1-complex models by protein-protein docking. The complex models were subjected to a 100-ns molecular dynamics simulation to assess the possible binding mode of the antibody.

Indexed as

BacteriophagesImmunoglobulin FragmentsHumansMatrix Metalloproteinase 9StaphylococcusStaphylococcus aureusImmunoglobulin FragmentsMatrix Metalloproteinase 9antivirulence strategyphage displayscFvstaphylococcal superantigen-like proteinStaphylococcus aureus

Identifiers

PMID37642487
PMCPMC10350561
OpenAlexW4384526213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.